Journal profile · Medicine-Oncology
Cancer Management and Research
ISSN 1179-1322 · Dove Medical Press Ltd. · UNITED STATES
Cancer Management and Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.62; fully open access; APC about USD 3,940; median 90 days to acceptance (111 articles, last 24 months); acceptance rate 10% (journal website); 276 articles in 2025; indexed in SCIE and Scopus; flagged on an early-warning list or for an indexing change: check before submitting.
Scope
Aims, scope and focus
Cancer Management and Research is published by Dove Medical Press Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer-related molecular mechanisms research, Circular RNAs in diseases and MicroRNA in disease regulation, together about 29.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Yong Teng Cancer Management and Research is part of our Elevate Series. This means that you will receive a concierge-level publishing experience, including dedicated support from our expert in-house Editorial team. Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. The journal welcomes submissions to the following sections:• Epidemiology & Prevention• Tumor Biology & Genetics• Biomarker Studies• Cancer Therapeutics (Basic/Translational)• Cancer Therapeutics (Clinical)• Cancer Imaging• Cancer Immunology• Radiation Oncology• Surgical Oncology• Palliative Care• Cancer Survivorship The journal welcomes the following article types on all aspects of oncology unless otherwise stated below. The journal will no longer consider meta-analyses for publication. The journal does not consider case reports except in circumstances where they make a valuable contribution to the literature. Cell line studies must demonstrate thorough and rigorous protocols, and biomarker association studies must be supported by in vivo validations. Tissue microarray analyses and single nucleotide polymorphism (SNP) studies will not be considered. When considering submission of a paper utilizing publicly available data (e.g. SEER/GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria. Updated 8 September 2026
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Yong TengPublisher website
Editorial board by country: 18 in mainland China (about 19%); most named United States 25, Mainland China 18, Italy 15, India 14, United Kingdom 5 (96 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology10.6%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology9.8%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology8.9%
- Inflammatory Biomarkers in Disease PrognosisMedicine6.4%
- Ferroptosis and cancer prognosisMedicine4.9%
- Cancer Immunotherapy and BiomarkersMedicine4.7%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine4.3%
- Lung Cancer Treatments and MutationsMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
Early warning / risk: CAS Early Warning Journal List: listed in the 2021 edition (medium risk); not listed in the other 5 editions.LetPub
Indexing the journal's website claims
PMCEmbasePublisher website
Other: The Open Access Initiative (OAIster)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.62LetPub ·
- Impact factor (publisher) 2025
- 2.5Publisher website ·
- 5-year impact factor (publisher)
- 4.4Publisher website ·
- CiteScore 2026-06
- 4.4LetPub ·
- CiteScore (publisher) 2025
- 0.86Publisher website ·
- SJR 2026-06
- 0.79LetPub ·
- SNIP 2026-06
- 0.86LetPub ·
- h-index
- 32LetPub ·
- h-index
- 93OpenAlex ·
- i10-index
- 3,105OpenAlex ·
- 2-year mean citedness
- 2.16OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.43%LetPub ·
Volume
- Articles per year
- 264LetPub ·
- Downloads per year (publisher)
- 528,140Publisher website ·
Articles by year OpenAlex count · 5,339 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 229 | 229 | 40 |
| 2025 | 276 | 276 | 657 |
| 2024 | 163 | 163 | 748 |
| 2023 | 153 | 153 | 1,076 |
| 2022 | 330 | 330 | 3,490 |
| 2021 | 891 | 891 | 12,053 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
90 daysMedian, submission to acceptance · P25–P75 73 days – 119 days
- Acceptance to online
- median 15 days (111 articles)
- Submission to online
- median 108 days
- Sample
- 111 articles with submission and acceptance dates (545 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 10%Publisher website ·
- Desk decision
- 44 daysPublisher website ·
- Submission to first decision
- 44 daysPublisher website ·
- Acceptance to publication
- 16 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,940 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Graphical abstract
- Optional
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Plagiarism
- Publication ethics
Member of and subscribes to the principles of the Committee on Publication Ethics (COPE) Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- Plagiarism
All submitted manuscripts are checked for plagiarism using Crossref Similarity Check (powered by iThenticate). Model summary
Please be aware that Dove Medical Press checks ALL submitted manuscripts for plagiarism. We use Crossref Similarity Check (powered by iThenticate).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press Ltd.
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 1179-1322
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cancer Management and Research
What CAS zone is Cancer Management and Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Management and Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Management and Research?
The latest impact factor listed by LetPub is 2.62; CiteScore 4.4, h-index 93.
How long does peer review take at Cancer Management and Research?
Based on the dates recorded on 111 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 90 days (interquartile range 73–119 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 10%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cancer Management and Research based?
Of the 96 board members whose country the journal's board page names, 18 (about 19%) are in mainland China; the countries named most often are United States (25), Mainland China (18) and Italy (15). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Management and Research?
According to LetPub and DOAJ records, Cancer Management and Research is indexed in SCIE, Scopus and DOAJ. The journal's website also lists PMC and Embase; that list has not been checked against each database.
Is Cancer Management and Research open access, and what is the APC?
Cancer Management and Research is a fully open-access journal. APC about USD 3,940.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .